00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
21:19 , Jun 13, 2019 |  BC Innovations  |  Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

Bypassing the metabolic conversion required for Schedule IV opiate tramadol to achieve analgesia, Syntrix has positioned desmetramadol as a safer and more effective pain therapy. Tramadol has been positioned as less likely to cause lethal...
14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
00:48 , May 17, 2019 |  BC Innovations  |  Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

Model-informed drug development is poised to move into personalized dosing, with a little help from exosomes. An August FDA workshop aims to shed light on when and how to use these precision dosing models in...
17:48 , Mar 28, 2019 |  BC Innovations  |  Translation in Brief

Tuning metabolism in liver organoids

An Alnylam-MIT collaboration has used RNAi technology to tune enzyme expression in hepatocyte-based organoids to better model drug metabolism during tox screens. The collaboration with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) built on a series of papers...
21:05 , Mar 25, 2019 |  BC Extra  |  Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: Transgenics and knockouts; pharmacokinetics/pharmacodynamics Rats expressing human UGT2 or CYP3A gene clusters could be used to predict the PK of drug compounds metabolized by the two enzyme families. Rats engineered to express the entire...
21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Mycobacterium Cell culture and mouse studies identified a carboxamide-based inhibitor of M. tuberculosis qcrB that could help treat Buruli ulcers, which are caused by M. ulcerans infection. In M. ulcerans growth assays, bacteria expressing...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...